Fortress Biotech Inc (FBIO)
1.625
+0.02
(+0.93%)
USD |
NASDAQ |
Oct 04, 16:00
1.625
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech SG&A Expense (Annual): 94.12M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 94.12M |
| December 31, 2022 | 113.66M |
| December 31, 2021 | 86.84M |
| December 31, 2020 | 61.17M |
| December 31, 2019 | 55.59M |
| December 31, 2018 | 53.37M |
| December 31, 2017 | 50.90M |
| Date | Value |
|---|---|
| December 31, 2016 | 35.16M |
| December 31, 2015 | 21.58M |
| December 31, 2014 | 10.41M |
| December 31, 2013 | 10.10M |
| December 31, 2012 | 8.665M |
| December 31, 2011 | 5.755M |
| December 31, 2010 | 0.90M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
55.59M
Minimum
2019
113.66M
Maximum
2022
82.28M
Average
86.84M
Median
2021
SG&A Expense (Annual) Benchmarks
| Journey Medical Corp | 43.91M |
| Checkpoint Therapeutics Inc | 8.685M |
| Avenue Therapeutics Inc | 4.179M |
| Phathom Pharmaceuticals Inc | 117.93M |
| NovaBay Pharmaceuticals Inc | 12.83M |